ClinicalTrials.gg
Active, not recruitingNCT07297797Updated Jul 31, 2026

Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

A Phase 2 interventional study of HRS-9563 Injection and sodium chloride injection in Mild to Moderate Hypertension, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Enrollment
161st of 308
238 · median 253
Started
2026
with 37 others
Phase 2
14 of 410
5 open now
Primary completion
2026-12
later than 65 of 147 live
Registered
360th of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 161st largest by enrollment of the 308 interventional ones that give a count, is one of 38 that started in 2026, is one of 14 in phase 2, reaches primary completion later than 65 of the 147 other live ones, and was the 360th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

119 more — sign in →

All 124 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 554 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.

03

Conditions studied

  • Mild to Moderate Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily signs the form.
  2. Male or female, aged ≥ 18 years and ≤ 75 years;
  3. Patients with mild to moderate hypertension;
  4. At the Screening and Baseline periods, the mean sitting office systolic blood pressure is > 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \< 160 mmHg.

Exclusion criteria

Exclusion Criteria:

  1. Secondary hypertension;
  2. Orthostatic hypotension;
  3. Type 1 diabetes or poorly controlled type 2 diabetes;
  4. Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening;
  5. Presence of uncontrolled severe arrhythmia within 6 months prior to screening;
  6. Suspected allergy to the drug or any of its components;
  7. Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension;
  8. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria;
  9. Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS-9563 or Placebo Injection; low dose

    Drug: HRS-9563 Injection · Drug: sodium chloride injection

  • Experimental
    Treatment group B: HRS-9563 or Placebo Injection; Intermediate dose

    Drug: HRS-9563 Injection · Drug: sodium chloride injection

  • Experimental
    Treatment group C: HRS-9563 or Placebo Injection; Medium to high dose

    Drug: HRS-9563 Injection · Drug: sodium chloride injection

  • Experimental
    Treatment group D: HRS-9563 or Placebo Injection; high dose

    Drug: HRS-9563 Injection · Drug: sodium chloride injection

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 6

    Time frame: at 6 months after initiation of administration

Secondary outcomes

  1. Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 3

    Time frame: at 3 months after initiation of administration

  2. Change from baseline in 24-hour mean diastolic blood pressure assessed by ABPM at month 3

    Time frame: at 3 months after initiation of administration

  3. Change from baseline in 24-hour mean diastolic blood pressure assessed by ABPM at month 6

    Time frame: at 6 months after initiation of administration

  4. Change from baseline in mean sitting office systolic blood pressure at month 3;

    Time frame: at 3 months after initiation of administration

  5. Change from baseline in mean sitting office systolic blood pressure at month 6;

    Time frame: at 6 months after initiation of administration

  6. Change from baseline in mean sitting office diastolic blood pressure at month 3;

    Time frame: at 3 months after initiation of administration

  7. Change from baseline in mean sitting office diastolic blood pressure at month 6;

    Time frame: at 6 months after initiation of administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's planned 11 months is below that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 22, 2025
StartActual
Jan 14, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Oct 2027
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07297797
Responsible party
Sponsor
First posted
Dec 22, 2025
Start date
Jan 14, 2026
Primary completion
Dec 2026 (estimated)
Completion
Oct 2027 (estimated)
Last update
Jul 31, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion